Dayany Leonel Boone

Dayany Leonel Boone

Auto-generated profile, based on publicly available information

Dayany Leonel Boone

Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
VTVitor Tumas
Vitor Tumas
MAMarcelo Jhonatan Aureliano
Marcelo Jhonatan Aureliano
CRCarlos R. M. Rieder
Carlos R. M. Rieder
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
HFHenrique B. Ferraz
Henrique B. Ferraz
IMIgnacio Fernandez Mata
Ignacio Fernandez Mata
The etiology of Parkinson's disease (PD) is complex and multifactorial, depending on interactions involving environmental/lifestyle and genetic factors. The genetic aspects of the disease are becoming well characterized, while the environmental factors still need further investigation. In the present narrative review, we have described the most concrete evidence of associations between environmental factors and the risk of developing PD. Physical activity, healthy dietary patterns, smoking, and caffeine intake are protective factors against PD. Head trauma, consumption of milk and dairy products, and pesticide exposure were associated with a higher risk of developing PD. The associations of alcohol consumption, living in rural areas, farming, and consumption of well water with PD are still controversial. Results of several studies strongly suggest that diabetes mellitus is a risk factor for the development of PD, as well as the pre-diabetic state. Lower serum levels of uric acid were associated with an increased risk of developing PD and with worse clinical features and faster progression of symptoms. The protective effects of nonsteroidal antiinflammatory drugs use are controversial. Several other factors were potentially associated with the risk of developing PD: environmental pollutants such as organic solvents, exposure to sunlight, vitamin D deficiency, bullous pemphigoid, bipolar disorder, inflammatory bowel disease, irritable bowel syndrome, certain infections and agents, and essential tremor. Environmental factors are important risk markers for the development of PD. Understanding these risks and protective factors could lead to the implementation of risk-modifying actions for PD.

20 April 2025 in Journal of Geriatric Psychiatry and Neurology
Verified
Journal Article
Closed access
MFMatheus de Medeiros Fernandes
Matheus de Medeiros Fernandes
LNLuis Otávio Souza Nogueira
Luis Otávio Souza Nogueira
IRIsabella Soares Marques Rabelo
Isabella Soares Marques Rabelo
LDLouise Dalla Corte Dallé
Louise Dalla Corte Dallé
ACAngela Maria Sandini Corso
Angela Maria Sandini Corso
DBDayany Leonel Boone
Dayany Leonel Boone
Introduction: Recent research in Parkinson’s disease (PD) has highlighted the potential therapies of continuous subcutaneous infusions (CSCI) of levodopa/carbidopa (ND0612) and foslevodopa/foscarbidopa (ABBV-951). This systematic review aims to explore their effectiveness and safety for PD. Methods: Guided by the PRISMA statement, we systematically searched 3 electronic databases: MEDLINE, Embase, and Cochrane Central. We combined quantitative and qualitative data for synthesis and descriptive analysis. Quality assessment and risk of bias were evaluated by ROBINS-1 and Rob-2 criteria. Results: We included 6 records with a total of 698 patients. CSCI therapies reduced motor symptoms in PD patients with levodopa-related motor fluctuations and clinical improvements. Infusions-site reactions were the main adverse event recorded. Conclusions: ND0612 and ABBV-951 are promising options for enhancing motor control and quality of life in PD patients. However, further research is needed to assess long-term efficacy, safety, and comparisons with oral levodopa and device-aided treatments.

19 March 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
LNLuis O. S. Nogueira
Luis O. S. Nogueira
RMRoberto A. S. V. Mazetto
Roberto A. S. V. Mazetto
MDMaria L. R. Defante
Maria L. R. Defante
VAVânio L. J. Antunes
Vânio L. J. Antunes
OGOcílio Ribeiro Gonçalves
Ocílio Ribeiro Gonçalves
HFHenrique B. Ferraz
Henrique B. Ferraz
Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials (RCTs) have shown mixed results regarding the use of this medication. Objective To perform a meta-analysis comparing GLP-1 agonists with placebo or standard PD treatment in adult PD patients. Methods We systematically searched the PubMed, Embase and Cochrane Central databases. The efficacy outcomes were assessed through the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39). We also assessed adverse events. Dichotomous data were compared using the risk ratio (RR), and continuous endpoints were pooled using the mean difference (MD). Results We included 4 RCTs, with a total of 514 patients. In every study, the Hoehn and Yahr stage was < 3. The pooled analysis demonstrated that the use of GLP-1 agonists was not associated with an improvement in the scores on parts I, II, III, and IV of the MDS-UPDRS at 6 and 12 months of follow-up. Neither did quality of life (PDQ-39) show significant differences among the groups, and a higher risk of gastrointestinal adverse events and weight loss was observed with the use of GLP-1 agonists. A subgroup analysis further confirmed the lack of clinical benefits of the intervention regarding all of these efficacy outcomes, and the intervention also significantly reduced result heterogeneity. Conclusion In 1 year, GLP-1 agonists failed to improve motor and non-motor features of PD. Additional high-quality studies are needed to draw more robust conclusions about this treatment.

5 March 2025 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
LNLuis Otávio Nogueira
Luis Otávio Nogueira
ACAngela Maria Sandini Corso
Angela Maria Sandini Corso
LDLouise Dalla Corte Dallé
Louise Dalla Corte Dallé
VAVanio L.J. Antunes
Vanio L.J. Antunes
MFMatheus de M. Fernandes
Matheus de M. Fernandes
DBDayany Leonel Boone
Dayany Leonel Boone
Background: Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is a well‐established treatment for Parkinson's Disease (PD). However, the long‐term trajectory of Quality of Life (QoL) following STN‐DBS remains underexplored.Objectives: We aimed to conduct a systematic review and meta‐analysis to assess QoL trends up to five years after STN‐DBS.Methods: We systematically searched PubMed, Embase, and Cochrane databases from inception to August 2024 for studies involving PD patients treated with bilateral STN‐DBS, evaluating QoL using the Parkinson's Disease Questionnaire (PDQ), with a minimum follow‐up of 12 months post‐surgery. Continuous outcomes were pooled using standardized mean differences (SMD), and statistical analyses were conducted using R version 4.3.2.Results: Out of 4106 screened articles, 42 studies with a total of 2767 patients were included in the meta‐analysis. QoL improvements were observed up to 36 months post‐surgery (SMD 0.83; 95% CI 0.29 to 1.37), followed by a decline to pre‐operative levels at 60 months (SMD ‐0.06; 95% CI ‐0.26 to 0.15). Subdomain analysis at 60 months revealed significant deterioration in cognitive function and communication. Meta‐regression indicated that QoL improvements were independent of clinical and sociodemographic factors such as age, sex, and disease duration; however, there was a correlation with mean baseline PDQ (P = 0.01).Conclusions: This meta‐analysis provides long‐term QoL trends following STN‐DBS, highlighting a further need to explore the factors driving the decline in QoL and develop strategies to mitigate this deterioration.

9 July 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
DBDayany Leonel Boone
Dayany Leonel Boone
VBVanderci Borges
Vanderci Borges
HFHenrique B. Ferraz
Henrique B. Ferraz
Parkinson's disease (PD) is a neurodegenerative disorder that differs between women and men in epidemiology, clinical manifestations, treatment response, adverse effects, and disease progression. The central hypothesis that sex hormones may modulate dopaminergic and neuroinflammatory/oxidative stress circuits could explain the observed clinical and epidemiological differences. These factors may influence motor and non-motor symptoms, pharmacological management, reproductive counseling, sexual health, and decisions regarding advanced therapies. In this narrative review, we synthesize current evidence and highlight key knowledge gaps on PD across the menstrual cycle, pregnancy, and menopause. We also discuss the potential role of estrogen exposure, menopausal hormone therapy, pregnancy-related medication considerations, deep brain stimulation (DBS) during pregnancy, and clinically relevant knowledge gaps. Available evidence remains limited, heterogeneous, and largely based on observational studies, case series, and expert opinion. Recognizing reproductive-stage influences may improve individualized care for women with PD and should be prioritized in future prospective research.

21 June 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
DBDayany Leonel Boone
Dayany Leonel Boone
VPVictor Rebelo Procaci
Victor Rebelo Procaci
HFHenrique B. Ferraz
Henrique B. Ferraz
OBOrlando G. P. Barsottini
Orlando G. P. Barsottini
JPJosé Luiz Pedroso
José Luiz Pedroso
The cerebellum and basal ganglia are integrated structures of the motor system, classically viewed as separate entities with different roles. Interactions between these structures were believed to occur mainly at the cortical level. However, neuroanatomical studies have resulted in a shift in this perspective. Symptoms attributed to basal ganglia disorders may arise from aberrant cerebellar circuit activity, and, conversely, cerebellar dysfunction may manifest due to pathological changes in basal ganglia pathways. In this narrative review, we present multiple disorders of the basal ganglia and cerebellum, highlighting their intricate interactions.